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Figure 1. Cognitive development estimated by the cognitive status at HCT.
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were used.
Results: Pharmacokinetic and -dynamic data were available
from 196 pediatric HCT’s (Table 1); 28 were excluded due to
2nd/3rd HCT (13) or antibodies (15). Post-HCT exposures
correlates best with the endpoints. 5-year probability of OS
and EFS were higher in patients with a low (<20 AU*days/L)
post-HCT AUC (p<0.01: OS according to AUC in ﬁg 2).
Multivariate predictors for lower OS were high (>20
AU*days/L) post-HCT AUC (p¼0.024), mismatch donor
(p¼0,01) and malignancy (p¼0,007). In addition, low post-
HCT AUC of Thymoglobulin was associated successful T-cell
reconstitution (p<0.005) while incidence of aGvHD
increased (p¼0.01), although the absolute increase of prob-
ability of aGvHD is less relevant (ﬁg 3).
Conclusion: High (>20 AU*days/L) post-HCT exposure of
Thymoglobulin is associated with a lower OS and a lower
probability of successful IR. These results may contribute to
individualized dosing guidelines of Thymoglobulin in chil-
dren, aiming to improved survival.Figure 3. Height estimated by the obtained leukocyte IDUA enzyme level.
Figure 2. Occurrence of surgical intervention for cord compression estimated
by the obtained leukocyte IDUA enzyme level.82
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Objectives: Hurler syndrome (HS), the most severe pheno-
type of Mucopolysaccharidosis type I, is caused by a deﬁ-
ciency of the lysosomal enzyme alpha-L-iduronidase (IDUA).
HS is clinically characterized by a progressive and ultimately
fatal multi-system deterioration with involvement of the
central nervous system (CNS). At present, hematopoietic cell
transplantation (HCT) is the only treatment able to prevent
disease progression in the CNS and therefore considered the
treatment of choice in HS. However, there is a lack of long-
term follow-up data on successfully transplanted HS pa-
tients as well as the factors inﬂuencing them. Therefore, this
international multicenter study was initiated to identify
predictors of the long-term outcome of successfully trans-
planted HS patients worldwide.
Methods: Alive and engrafted HS patients with at least 3
years follow-up after HCT were retrospectively evaluated. The
main endpoint included the neurodevelopmental outcome;
secondary endpoints included the growth, neurologic, ortho-
pedic, cardiac, respiratory, ophthalmologic, audiologic andendocrinologic outcome. The inﬂuence of patient, donor, and
transplantation-related variables on these endpoints was
analyzed using multivariate Cox proportional hazards, logistic
regression, and linear mixed models.
Results: 197 HS patients from 10 transplantation centers
within Europe and the United States were included. This is
estimated to represent about 70% of the HS patients suc-
cessfully transplanted worldwide till 2008. Patients had a
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median follow-up of 8.9 (3-22.6) years after last HCT. Post-
transplant leukocyte IDUA enzyme levels below the lower
reference were seen in 25% of patients due to mixed-
chimerism or the use of a carrier donor. Following successful
HCT, the clinical course of HS patients is strikingly improved,
evident in all organ systems. Residual disease burden is
present in the majority of the patients with high variability
between patients. A better cognitive status at HCT was a
major predictor for superior cognitive development after
HCT (ﬁgure 1). Signiﬁcant predictors for superior long-term
outcome in all organ systems were the presence of “normal
IDUA enzyme levels obtained after HCT” and a “younger
age at transplantation”. See the association between the
leukocyte IDUA enzyme level obtained after HCTand surgical
intervention for cord compression and growth, in ﬁgure 2
and 3 respectively.
Conclusion: Although HCT signiﬁcantly improved the
clinical course in HS patients, residual disease burden was
observed in the majority of transplanted HS patients.
Using exclusively non-carrier donors and accepting only
full donor-chimerism will improve the prognosis of
HS patients. Reducing the age at HCT through newborn
screening could further improve the outcomes of HS pa-
tients after HCT.83
Allogeneic Stem Cell Transplantation for Children with
Sickle Cell Disease Achieves Quality of Life Similar to
Normal Children and Is Cost Effective
Staci Arnold 1, Zhezhen Jin 2, Alan Weinberg 3,4,
Jacquelyn Bishop 5, Stephen Sands 1, Maureen Licursi 1,
Monica Bhatia 6, Andrew Kung 6, Prakash Satwani 6. 1Columbia
University Medical Center, New York, NY; 2Biostatistics,
Columbia University, New York, NY; 3Health Evidence and
Policy, Mount Sinai Hospital, New York, NY; 4Health Policy and
Management, Columbia University Medical Center, New York,
NY; 5Pediatrics, New York Presbyterian Hospital, NewYork, NY;
6Pediatrics, Columbia University, New York, NY
Allogeneic stem cell transplantation (alloSCT) remains the
only curative option for sickle cell disease (SCD). However, no
systematic analysis exists comparing cost and quality of life
(QOL) among this population. We investigated the QOL
outcomes and health care utilization associated with alloSCT
in children with SCD.
Internal ﬁnancial data from 2002-2011 was analyzed retro-
spectively across two groups e post-alloSCT patients
(>day+365) and patients with SCD referred for alloSCT and/
or HLA typed. Surviving alloSCT recipients (A) and SCD
controls (B) were surveyed with age appropriate Pediatric
Quality of Life Inventory (PedsQLa) and EuroQOL (EQ-5Da)Post-AlloSCT
(>D+365, group A)
Controls
(group B)
p-value
Mean outpatient visits 0.93 1.81 <0.0001
Mean outpatient cost ($) 831.10 739.2 0.840
Mean outpatient cost
per QOL ($/QALM)
723.67 442.16 0.3506
Mean inpatient visits 0.02 0.52 <0.0001
Length of stay 0.06 1.05 <0.0001
Mean inpatient cost ($) 293.80 2050.20 0.115
Mean inpatient cost
per QOL ($/QALM)
345.69 769.08 0.0023questionnaires. Group A siblings without SCD (C) were also
surveyed as unaffected controls. Mean QOL scores were
calculated for each group with a max score of 100. Utility
scores were determined based on EQ-5D responses. These
scores and costs for groups A and B were used to calculate
cost per quality adjusted life month (QALM) for the cohort of
patients surveyed. Wilcoxon test was used to determine
statistical signiﬁcance.
Group A, B, and C had 16 (mean age - 14yrs), 19 (mean age -
12yrs), and 14 children (mean age - 14yrs), respectively. SCD
therapy included hydroxyurea (group A n¼8, group B n¼10)
and chronic transfusions (group A n¼7, group B n¼2). Mean
PedsQL scaled scores were 83, 81, and 88, respectively. Mean
EQ-5D visual analogue scale scores were 92, 87, 96, respec-
tively. Mean utility scores were 0.87, 0.91, and 0.89, respec-
tively. All QOL scores were not statistically signiﬁcant (p ¼
0.2638). Healthcare utilization among groups A and B was
previously reported (see details in table below). The median
inpatient cost per QALM for group A was $0 and $514 for
group B (p ¼ 0.0023). Outpatient cost per QALM for group A
was $353 and $236 for group B (p ¼ 0.3506).
SCD patients’ post-alloSCT QOL scores are similar to unaf-
fected siblings, indicating that QOL has normalized. Controls
with SCD also had scores similar to unaffected controls.
However, a statistically signiﬁcant difference exists in the
inpatient cost per QALM post-alloSCT compared to controls
with SCD. Outpatient was not signiﬁcant which may reﬂect
the limitations of the study period as post-alloSCT QOL and
cost can change over time (Felder-Puig 2006; Majhail 2010).
Ultimately, this study provides the ﬁrst combined analysis of
QOL as an outcome and the economic impact of alloSCT for
pediatric SCD patients. Further analysis is ongoing to afﬁrm
that alloSCT is a beneﬁcial and cost effective management
option for patients.84
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Background: Children, adolescents, and young adults
(CAYA) with Acute Leukemia in third complete remission
